Adamas Pharma (ADMS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2014 | 12-2013 | 09-2013 | 06-2013 | 03-2013 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 79,799 | 85,612 | N/A | N/A | N/A |
| Receivables | 251 | 129 | N/A | N/A | N/A |
| TOTAL | $80,592 | $86,008 | $N/A | $N/A | $N/A |
| Non-Current Assets | |||||
| PPE Net | 254 | 199 | N/A | N/A | N/A |
| Other Non-Current Assets | 1,949 | 9 | 0 | 0 | 0 |
| TOTAL | $2,203 | $208 | $N/A | $N/A | $N/A |
| Total Assets | $82,795 | $86,216 | $N/A | $N/A | $N/A |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,985 | 2,097 | 0 | 0 | 0 |
| Accrued Expenses | 2,430 | 2,119 | N/A | N/A | N/A |
| Other current liabilities | 4 | 2 | N/A | N/A | N/A |
| TOTAL | $4,419 | $4,218 | $N/A | $N/A | $N/A |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 4,020 | 6,244 | 0 | 0 | 0 |
| TOTAL | $4,031 | $6,244 | $N/A | $N/A | $N/A |
| Total Liabilities | $8,450 | $10,462 | $N/A | $N/A | $N/A |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 16,708 | N/A | N/A | N/A | N/A |
| Common Shares | 14 | 14 | N/A | N/A | N/A |
| Retained earnings | -26,952 | -20,572 | N/A | N/A | N/A |
| Other shareholders' equity | 23,013 | 19,149 | 0 | 0 | 0 |
| TOTAL | $74,345 | $75,754 | $N/A | $N/A | $N/A |
| Total Liabilities And Equity | $82,795 | $86,216 | $0 | $0 | $0 |